←
Joe Levy367 posts
Joe Levy avatar

Joe Levy

@jlevy2

Health economist @JohnsHopkinsSPH @JHSPH_HPM

◷ Joined January 2011▧ 19 Photos and videos
JAMA avatar
⟳ Joe Levy retweeted
JAMA@JAMA_current·Jul 9

Nearly one-third of first-time #prescription attempts for single-source branded drugs in the US were rejected due to formulary exclusion or utilization management, with more than 48% resulting in no dispensed therapy in the same class within 90 days. ja.ma/4vnWIZg

Post attachment
Ben Ippolito avatar
⟳ Joe Levy retweeted
Ben Ippolito@ben_ippolito·Jul 9

We have a new paper in @JAMA_current documenting the now-ubiquitous nature of formulary management for brand drugs By 2024, 40% (!) of initial attempts to fill a brand drug were rejected for prior auth or formulary exclusion (most of the growth over time is more prior auth)

Post attachment
Ben Ippolito avatar
⟳ Joe Levy retweeted
Ben Ippolito@ben_ippolito·Apr 29

Under the IRA, Part D plans have responded to lower out-of-pocket limits with higher deductibles The result is a sharp "tilting" of OOP spending through the year. Average OOP costs for brand fills are now higher in January, but sharply lower in later months as people hit the cap

Post attachment
Loren Adler avatar
⟳ Joe Levy retweeted
Loren Adler@LorenAdler·15 Aug 2024

Very interesting to get a deeper look at what Medicare coverage of the weight loss drugs might cost, taking into account existing rebates & considering the counterfactual that many are likely to gain coverage through other indications over time regardless.

Tough day for a 🚨new paper🚨, but nevertheless! How much would it cost if Medicare was allowed to cover drugs approved for weight loss? We estimate $3.1-6.1 billion per year in the near term. Just out in @Health_Affairs (with @jlevy2) healthaffairs.org/doi/10.137…

Ben Ippolito avatar
⟳ Joe Levy retweeted
Ben Ippolito@ben_ippolito·15 Aug 2024

Tough day for a 🚨new paper🚨, but nevertheless! How much would it cost if Medicare was allowed to cover drugs approved for weight loss? We estimate $3.1-6.1 billion per year in the near term. Just out in @Health_Affairs (with @jlevy2) healthaffairs.org/doi/10.137…

Angela Liu avatar
⟳ Joe Levy retweeted
Angela Liu@Angela_HSR·9 Aug 2024

🚨 New publication alert 🚨 I am so excited to share that I published part of my dissertation work in JAMA HF. A huge thank you to these co-authors: @KellyAnders0n, @jlevy2, @healthecon_dan, and the twitterless Thomas V Johnson and Jerry Anderson jamanetwork.com/journals/jam…

Kelly Anderson avatar
⟳ Joe Levy retweeted
Kelly Anderson@KellyAnders0n·27 Feb 2024

We've drafted a response to the recent CMS RFI on additional data collection to study the Medicare Advantage program. Want to sign on? Send me an email by Friday March 8th docs.google.com/document/d/1…

Ben Ippolito avatar
⟳ Joe Levy retweeted
Ben Ippolito@ben_ippolito·23 Oct 2023

Ozempic, Wegovy, and other GLP-1s perfectly illustrate the common (and large) gaps between list and net prices of many brand drugs. A summary of our work: "Ozempic and Wegovy Don’t Cost What You Think They Do" via @nytimes nytimes.com/2023/10/22/healt…

Ben Ippolito avatar
⟳ Joe Levy retweeted
Ben Ippolito@ben_ippolito·28 Sep 2023

Now in print, @jlevy2 and I test whether coverage of brand drugs in Part D differs based on whether the drug is a "good" or "bad" value relative to cost-effectiveness estimates. In short, it does not. aei.org/research-products/wo…

Ben Ippolito avatar
⟳ Joe Levy retweeted
Ben Ippolito@ben_ippolito·18 Sep 2023

Defining “the price” of brand drugs like Ozempic can be complex. Our white paper summarizes what we know about the prices of new treatments for diabetes and obesity Short story: Very big differences between list and net prices, even adjusting for coupons aei.org/research-products/re…

Mike DiStefano avatar
⟳ Joe Levy retweeted
Mike DiStefano@DiStefano_MJ·7 Sep 2023

CMS will use comparative effectiveness to adjust the starting point in price negotiations, but how exactly? We adapted the French system (added benefit ratings linked to domestic reference prices) to model one approach and estimate savings. @jlevy2 valueinhealthjournal.com/art…

Jeff Marr avatar
⟳ Joe Levy retweeted
Jeff Marr@jeffreydmarr·5 Sep 2023

New paper out in @health_affairs In Medicare Advantage, less use of longitudinal home-based medical care but substantially greater use of one-time home-based medical visits (likely related to diagnosis coding) than in traditional Medicare healthaffairs.org/doi/full/1…